Immupharma PLC Audited Report & Accounts published on website (4797L)

TIDMIMM

RNS Number : 4797L

Immupharma PLC

30 April 2020

RNS: RELEASE 30 April 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

Audited Report & Accounts published on website

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts ("Report") for the year ended 31 December 2019, has today been published on the Company's website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in the near future.

Confirmation of this date will be announced to the market on the day of posting. To view the Report please go to: www.immupharma.co.uk.

 
  For further information please contact: 
    ImmuPharma PLC ( www.immupharma.com ) 
     Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
    Dimitri Dimitriou, Chief Executive Officer 
    Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
    SPARK Advisory Partners Limited (NOMAD) 
     Neil Baldwin 
     Stanford Capital Partners (Joint Broker) 
     Patrick Claridge, John Howes                  +44 (0) 203 36 8 8974 
     SI Capital (Joint Broker)                      +44 (0) 203 815 8880 
     Nick Emerson                                   +44 (0) 1483 413500 
    4Reliance (Euronext Growth Listing Sponsor) 
     Jean-Charles Snoy 
 
     Degroof Petercam (Liquidity Provider) 
     Erik De Clippel 
                                                   +32 (0) 2 747 02 60 
     Backstage Communication                        +32 (0) 2 287 95 34 
     Olivier Duquaine                               +32 (0) 477 504 784 
     Gunther De Backer                              +32 (0) 475 903 909

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSIMMPTMTAJMJM

(END) Dow Jones Newswires

April 30, 2020 04:57 ET (08:57 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024